Edasalonexent
- Generic Name
- Edasalonexent
- Drug Type
- Small Molecule
- Chemical Formula
- C31H42N2O3
- CAS Number
- 1204317-86-1
- Unique Ingredient Identifier
- AF3Z6434KS
- Background
Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Catabasis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT04543370
- Locations
- ๐บ๐ธ
Celerion Clinical Research Unit, Tempe, Arizona, United States
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Catabasis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT03917719
- Locations
- ๐บ๐ธ
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
๐บ๐ธBoston Children's Hospital, Boston, Massachusetts, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Catabasis Pharmaceuticals
- Target Recruit Count
- 131
- Registration Number
- NCT03703882
- Locations
- ๐บ๐ธ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐จ๐ฆAlberta Children's Hospital, Calgary, Alberta, Canada
๐บ๐ธChildren's Hospital of the King's Daughters, Norfolk, Virginia, United States
Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Catabasis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02439216
A Study of CAT-1004 Biomarkers in Healthy Subjects
- Conditions
- Assessment of Mechanistic Blood Biomarkers in Healthy Humans
- Interventions
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Catabasis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01670773
- Locations
- ๐บ๐ธ
ProMedica, Brighton, Massachusetts, United States
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Catabasis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT01511900
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.